Clinica BavieraFRA:D9Z -1.43%100 EV-to-FCF is 20.42 as of Jul. 01, 2026, which is 53% above its 10-year median of 13.33. GuruFocus rates FRA:D9Z with a GF Score™ of 100/100 and a GF Value™ of €41.30 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 59.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Clinica Baviera's Enterprise Value is €927.6 Mil.
Clinica Baviera's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €45.4 Mil. Therefore, Clinica Baviera's EV-to-FCF for today is 20.42.
The historical rank and industry rank for Clinica Baviera's EV-to-FCF or its related term are showing as below:
FRA:D9Z'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.64 Med: 13.33 Max: 90.59
Current: 19.57
During the past 13 years, the highest EV-to-FCF of Clinica Baviera was 90.59. The lowest was 5.64. And the median was 13.33.
FRA:D9Z's EV-to-FCF is ranked better than 59.79% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.51
vs FRA:D9Z: 19.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clinica Baviera's PE Ratio (TTM) for today is calculated as:
Clinica Baviera's share price for today is €55.00.
Clinica Baviera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.739.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Clinica Baviera EV-to-FCF Related Terms
Clinica Baviera EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Clinica Baviera's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's EV-to-FCF falls into.
Clinica Baviera's current Enterprise Value is €927.6 Mil.
Clinica Baviera's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €45.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera (FRA:D9Z) has a EV-to-FCF of 20.42 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clinica Baviera and its competitors. This is 53% above median its historical median of 13.33. Over the past decade, Clinica Baviera's EV-to-FCF has ranged from 5.64 to 90.59. According to the industry distribution chart, Clinica Baviera ranks #39 out of 97 companies in the Medical Diagnostics & Research industry, placing it in the top 40.2%.
Is Clinica Baviera's EV-to-FCF too high?
Clinica Baviera's current EV-to-FCF of 20.42 is 53% above median its 10-year median of 13.33. Over the past 10 years, this metric has ranged from a low of 5.64 to a high of 90.59. The Medical Diagnostics & Research industry median EV-to-FCF is 22.51. Clinica Baviera's value of 20.42 is 9.3% below this industry median. Based on the distribution chart, Clinica Baviera ranks #39 out of 97 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #39 out of 97 companies for EV-to-FCF. This puts Clinica Baviera in the upper half of its industry. The industry median EV-to-FCF is 22.51. Clinica Baviera's value of 20.42 is 9.3% below this benchmark. Historically, Clinica Baviera's own EV-to-FCF has ranged from 5.64 to 90.59 over the past decade. While the company's 10-year median is 13.33 vs. the industry median of 22.51, Clinica Baviera has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.51, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current EV-to-FCF of 20.42 is 9.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current EV-to-FCF is 20.42, which is 53% above median its own 10-year median of 13.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (FRA:D9Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.30, compared to a current price of €55.00 — trading 33.2% above its estimated fair value. The current EV-to-FCF is 20.42, which is 53% above median its 10-year median of 13.33 and 9.3% below the Medical Diagnostics & Research industry median of 22.51. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Clinica Baviera (FRA:D9Z), the current EV-to-FCF is 20.42 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (FRA:D9Z) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €55.00 is trading 33.2% above its estimated GF Value™ of €41.30.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for FRA:D9Z:
EV-to-FCF: 20.42 (53% above median its 10-year median of 13.33)
GF Value™: €41.30 vs. price of €55.00 (33.2% above fair value)
Industry Position: 9.3% below the Medical Diagnostics & Research median (#39 of 97)
No single metric tells the full story. See the FRA:D9Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for FRA:D9Z
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D9Z has been successfully added to your 
